login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Phase 3 Trial Results of Ustekinumab Shows Possible Control of Psoriasis
October 05, 2007 at 5:44 PM
Drug News
The findings of the Phase 3 study showed that more than two-thirds of patients with moderate to severe plaque psoriasis receiving two doses of ustekinumab (CNTO 1275) achieved at least a 75 percent reduction in psoriasis at week 12, the primary endpoint of the study, as measured by the Psoriasis Area and Severity Index (PASI 75). Importantly, findings also showed that following one additional dose at week 16, a substantial proportion of patients receiving ustekinumab maintained a PASI 75 response through week 28. Data from the study presented at the World Congress of Dermatology, involved more than 1,200 subjects and showed that within four weeks of initiating treatment with ustekinumab, patients experienced significant and clinically meaningful improvements in quality of life measures compared with patients receiving placebo. Ustekinumab is a new, fully-human monoclonal antibody with a novel mechanism of action that targets the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), and is currently in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis.
These data, presented at the 21st meeting of the World Congress of Dermatology, will be the subject of a live press briefing and webcast (www.cnto1275wcd.com) today at 2 p.m. EDT featuring Craig Leonardi, MD, St. Louis University Medical School, St. Louis, MO, Kristian Reich, MD, Georg-August-University, Göttingen, Germany, Silvia Fernandez Barrio, executive director, Civil Association of Psoriasis Patients of Argentina, Buenos Aires, Argentina, and Tom Schaible, PhD, vice president, Medical Affairs, Centocor, Inc.
|
|
|
More News on: Psoriasis
 Comment & Contribute
|
|
11/11/2008
is ustekinumab available to purchase and if so where from
Reply |
Forward
|
Medwonders Health Network
- Health News Index
 | Quiz on Psoriasis Psoriasis is an autoimmune skin disease occurring in almost all parts of the body and affecting people of all ages. 
|
- News Quick Links
 |
Psoriasis
Complete Medindia Resources
|
| News Categories: |
| » | Cardio-Pulmonary Function can be a Strong Indicator for Survival Chances of Breast Cancer Patients |
| » | Post Surgery Will the Tumour Return? New Breast Cancer Test to Predict Exactly |
| » | Scientists Develop Compound That Triggers Cancer Cell Death |
| » | Iraqi National Hopes to Find Affordable Treatment for His Cancer in India |
| » | New Technique can Help Doctors Detect Pancreatic Cancer |
| More Cancer News | |
|
